Niedrobnokomórkowy rak płuca: badanie fazy II/III leku izalontamab brengitecan i cisplatin
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI…